Insulin degludec lowers nocturnal hypoglycaemia
Of the 629 participants, 472 were randomly assigned to insulin degludec and 157 to insulin glargine. At one year, HbA1c levels had fallen by 0.40% points in the degludec group, and 0.39% points in the glargine group.
Rates of overall confirmed hypoglycaemia and serious adverse events were similar in both groups, but confirmed nocturnal hypoglycaemia was 25% lower with degludec than with glargine.
Participants treated with insulin degludec were also using less basal,